Journal: Laboratory investigation; a journal of technical methods and pathology

Article Title: Low Doses of Celecoxib Attenuate Gut Barrier Failure During Experimental Peritonitis

doi: 10.1038/labinvest.2013.119

Figure Lengend Snippet: (a) H&E-stained sections of ileum from mice 16 h after injection with NS, injection with 40 mg/kg LPS, sham operation, or CLP. Note abundant epithelial sloughing in animals injected with LPS or subjected to CLP. Data are representative of at least 9 animals in each group. (b) Transepithelial passage of FITC-dextran and bacteria during peritonitis. Mice were gavaged with FITC-dextran and E. coli 35354T prior to indicated treatments. Serum concentrations of FITC-dextran (top) and counts of viable E. coli in combined mesenteric lymph nodes and spleens (bottom) were determined 16 h post treatment. *, Significant differences (p ≤ 0.01, n ≥ 12 in each group). (c) Localization of JAM-A (red) in ileal epithelium 16 h after indicated treatments. Note increased re-distribution of JAM-A from borders to intracellular space of enterocytes in LPS and CLP samples. (d) Localization of ZO-1 (red) in ileal epithelium 16 h after indicated treatments. Note increased redistribution of ZO-1 from TJ to intracellular space of enterocytes in LPS and CLP samples. DAPI-stained nuclei appear in blue. Bar=50 μm. All images are representative of at least 3 animals in each group.

Article Snippet: Commensal E. coli strain 35354T was obtained from ATCC (Manassas, VA) and transformed with the pUC18 plasmid to confer ampicillin resistance.

Techniques: Staining, Injection, Bacteria

Journal: Laboratory investigation; a journal of technical methods and pathology

Article Title: Low Doses of Celecoxib Attenuate Gut Barrier Failure During Experimental Peritonitis

doi: 10.1038/labinvest.2013.119

Figure Lengend Snippet: Mice were gavaged with the test mixture of FITC-dextran and E. coli prior to experiments. Celecoxib at indicated doses (mg/kg) or vehicle were added to the test mixture. (a) Serum FITC-dextran levels 16 h after injection with NS or LPS, with or without various doses of Celecoxib, as indicated. (b) Serum FITC-dextran levels 16 h after sham operation or CLP, with or without various doses of Celecoxib, as indicated. (c) E. coli counts in lymphatic organs 16 h after injection with NS or LPS, with or without various doses of Celecoxib, as indicated. (d) E. coli counts in lymphatic organs 16 h after sham operation or CLP, with or without Celecoxib, as indicated. (e) E. coli counts in liver 16 h after indicated treatments, with or without 0.5 mg/kg Celecoxib, as indicated. Data are average ± SEM, n≥12 in each group. Significant differences: *, p ≤0.01 vs. LPS or CLP alone; **, p≤0.02 vs. LPS or CLP alone; #, p≤0.02 vs. NS or sham.

Article Snippet: Commensal E. coli strain 35354T was obtained from ATCC (Manassas, VA) and transformed with the pUC18 plasmid to confer ampicillin resistance.

Techniques: Injection